SCHEMBL6097501

SCHEMBL6097501

O=C(C=Cc1ccc([N+](=O)[O-])cc1)Nc1ccccc1C(=O)Nc1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.72
CYP3A4 P08684 1/20 0.72
CYP2C9 P11712 1/20 0.72
TRPM2 O94759 2/20 0.61
HTT P42858 2/20 0.60
RECQL P46063 1/20 0.60
SMN1; SMN2 Q16637 4/20 0.57
MEN1 O00255 3/20 0.57
MAPT P10636 4/20 0.57
NPC1 O15118 3/20 0.57
RAB9A P51151 3/20 0.57
POLB P06746 2/20 0.57
ALDH1A1 P00352 2/20 0.57
HDAC1 Q13547 1/20 0.56
LTB4R Q15722 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
ABCG2 Q9UNQ0 1/20 0.54
MMP1 P03956 1/20 0.53
MMP2 P08253 1/20 0.53
MMP9 P14780 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6525729 0.88 TRPM2 (0.76) KMT2ACYP3A4CYP2C9TRPM2HTT
SCHEMBL6525728 0.88 TRPM2 (0.76) KMT2ACYP3A4CYP2C9TRPM2HTT
SCHEMBL6100523 0.86 HTT (0.74) KMT2ATRPM2HTTRECQLSMN1; SMN2
SCHEMBL6100516 0.86 HTT (0.74) KMT2ATRPM2HTTRECQLSMN1; SMN2
4-Nitro-Cinnamanilide SCHEMBL3021597 0.86 MAPT (0.72) KMT2ASMN1; SMN2MEN1MAPTNPC1
SCHEMBL6100616 0.82 KMT2A (0.64) KMT2ACYP3A4CYP2C9TRPM2HTT
SCHEMBL6097507 0.81 MEN1 (0.75) KMT2AHTTRECQLSMN1; SMN2MEN1
SCHEMBL15306486 0.81 MMP1 (0.69) KMT2ASMN1; SMN2MEN1MAPTNPC1
SCHEMBL3021602 0.81 MMP1 (0.69) KMT2ASMN1; SMN2MEN1MAPTNPC1
4-Nitro-(4'-Nitro)Cinnamanilide SCHEMBL5315660 0.79 KMT2A (0.70) KMT2AHTTSMN1; SMN2MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053216-B2 Modulators of Rho C activity ICONIX PHARMACEUTICALS, INC. (US) 2006-05-30 US disclosed
US-20030171387-A1 Modulators of Rho C activity ENTELOS HOLDING CORP. 2003-09-11 US disclosed
WO-2003043961-A2 MODULATORS OF RHO C ACTIVITY ICONIX PHARMACEUTICALS, INC. (US) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171387-A1 Modulators of Rho C activity RHOC, ROCK1, CIT KMT2A 3564/4885CYP3A4 2850/4885CYP2C9 2362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.